Last Price
13.50
Today's Change
-3.32 (19.73%)
Day's Change
12.48 - 17.41
Trading Volume
3,229,892
Market Cap
701 Million
Shares Outstanding
51 Million
Avg Volume
881,755
Avg Price (50 Days)
16.83
Avg Price (200 Days)
22.26
PE Ratio
-6.03
EPS
-2.24
Earnings Announcement
07-Nov-2024
Previous Close
16.82
Open
17.39
Day's Range
12.48 - 17.41
Year Range
9.44 - 36.25
Trading Volume
3,229,892
1 Day Change
-19.74%
5 Day Change
-15.73%
1 Month Change
-8.23%
3 Month Change
-40.29%
6 Month Change
-57.84%
Ytd Change
-36.47%
1 Year Change
-9.88%
3 Year Change
-59.53%
5 Year Change
-66.67%
10 Year Change
-66.67%
Max Change
-66.67%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.